Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Marijuana Inc (MAJI)

Marijuana Inc (MAJI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
NexTel Medical Corp Enters Final Stage for Commercial Launch; Sets Sights on Revenue Generation and OTCQB Uplist GlobeNewswire - Mon May 11, 10:53AM CDT

ORLANDO, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI) , a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery...

MAJI : 0.0106 (-3.64%)
NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test GlobeNewswire - Tue Apr 7, 9:30AM CDT

ORLANDO, Fla., April 07, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp f/k/a Exousia Pro, Inc. ( OTCPK: MAJI ), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery...

MAJI : 0.0106 (-3.64%)
Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value GlobeNewswire - Mon Mar 16, 9:15AM CDT

ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, today announced the...

MAJI : 0.0106 (-3.64%)
Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions GlobeNewswire - Thu Mar 5, 12:00PM CST

ORLANDO, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI) , a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is pleased to announce...

MAJI : 0.0106 (-3.64%)
Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition GlobeNewswire - Tue Feb 10, 9:30AM CST

ORLANDO, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCID: MAJI) , a clinical-stage biotechnology company specializing in proprietary exosome-based delivery systems, is pleased to announce...

MAJI : 0.0106 (-3.64%)
Exousia Pro Will Launch a Web Series with Our New Consultant ACCESS Newswire - Wed Apr 30, 2025

Dr. Marvin Hausman is joining Exousia Pro as a Consultant and will host a weekly series.

MAJI : 0.0106 (-3.64%)
Exousia Pro Finishes Preclinical Trial for Glioblastoma Ahead of Schedule - Bolstering Orphan Drug Application ACCESS Newswire - Tue Apr 29, 2025

- Rigorous humanized mouse model enhances credibility and translatability of results

MAJI : 0.0106 (-3.64%)
Exousia Pro CSO Revealed Significant Findings About the Glioblastoma Study in a Spaces Interview ACCESS Newswire - Mon Apr 21, 2025

A published paper shows NANOG Expression was almost 100% effective at eradicating tumor cells

MAJI : 0.0106 (-3.64%)
Exousia Pro Offers Guidance on New Subdivisions ACCESS Newswire - Thu Apr 17, 2025

ORLANDO, FL / ACCESS Newswire / April 17, 2025 / MARIJUANA INC. (OTCPINK:MAJI), dba Exousia Pro, a clinical-stage biotech company utilizing exosomes in the treatment of cancer and other diseases, is pleased...

MAJI : 0.0106 (-3.64%)
Exousia Pro to Deliver 500 Billion Dried Exosomes for Trade Show ACCESS Newswire - Tue Apr 8, 2025

Exousia Pro has a 60% margin built-in on each order of exosomes

MAJI : 0.0106 (-3.64%)

Barchart Exclusives

Workday Stock Pops on Earnings Results. A Long-Awaited Turnaround Could Finally Be Here. Barchart - 26 minutes ago
Workday stock jumped 5% after beating Q1 earnings estimates and raising its full-year margin forecast. Here's why this could be the start of something bigger. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.